Pharmacometabolomics of Asthma as a Road Map to Precision Medicine

0Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pharmacometabolomics applies the principles of metabolomics to therapeutics in order to elucidate the biological mechanisms underlying the variation in responses to drugs between groups and individuals. Asthma is associated with broad systemic effects and heterogeneity in treatment response and as such is ideally suited to pharmacometabolomics. In this chapter, we discuss the state of the emerging field of asthma pharmacometabolomics, with a particular focus on studies of steroids, bronchodilators, and leukotriene inhibitors. We also consider those studies concerned with subtyping cases to better understand the pharmacology of those groups and those looking to leverage pharmacometabolomics for asthma prevention. We finish with a discussion of the challenges and opportunities of asthma pharmacometabolomics and reflect upon where this field must go next in order to realize its precision medicine potential.

Cite

CITATION STYLE

APA

Kelly, R. S., Cote, M. F., Begum, S., & Lasky-Su, J. (2023). Pharmacometabolomics of Asthma as a Road Map to Precision Medicine. In Handbook of Experimental Pharmacology (Vol. 277, pp. 247–273). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/164_2022_615

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free